Search research articles
Contact Us
Filters
Showing results (1-10 of 162) with videos related to
Page
of 17
Sort By:
Stroke
|
January 10, 2015
You may have worked on more adaptive designs than you think
Christopher S Coffey
Statistics in Medicine
|
July 23, 2003
Properties of internal pilots with the univariate approach to repeated measures
Christopher S Coffey, Keith E Muller
The Lancet. Neurology
|
September 19, 2019
Antisense oligonucleotides might change the therapeutic landscape for Huntington's disease
Jane S Paulsen, Christopher S Coffey
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences
|
May 2, 2002
Two-stage testing in microarray analysis: what is gained?
David B Allison, Christopher S Coffey
Neurology
|
April 15, 2009
Stroke trials: a shift to shift analysis?
Devin L Brown, Christopher S Coffey
Communications in Statistics: Theory and Methods
|
January 28, 2014
Properties of Doubly-Truncated Gamma Variables
Christopher S Coffey, Keith E Muller
Drugs in R&D
|
July 1, 2008
Adaptive clinical trials: progress and challenges
Christopher S Coffey, John A Kairalla
Communications in Statistics: Theory and Methods
|
December 6, 2013
Some Distributions and Their Implications for an Internal Pilot Study With a Univariate Linear Model
Christopher S Coffey, Keith E Muller
Clinical Trials (London, England)
|
February 5, 2013
Monitoring futility in a two-by-two factorial design: the SPS3 experience
Leslie A McClure, Christopher S Coffey, George Howard
Stroke
|
June 11, 2005
Is Bayesian analysis ready for use in phase III randomized clinical trials? Beware the sound of the sirens
George Howard, Christopher S Coffey, Gary R Cutter
Page
of 17
Search research articles
Search
Showing results (1-10 of 162) with videos related to
Sort By:
Page
of 17
Stroke
|
January 10, 2015
You may have worked on more adaptive designs than you think
Christopher S Coffey
Statistics in Medicine
|
July 23, 2003
Properties of internal pilots with the univariate approach to repeated measures
Christopher S Coffey, Keith E Muller
The Lancet. Neurology
|
September 19, 2019
Antisense oligonucleotides might change the therapeutic landscape for Huntington's disease
Jane S Paulsen, Christopher S Coffey
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences
|
May 2, 2002
Two-stage testing in microarray analysis: what is gained?
David B Allison, Christopher S Coffey
Neurology
|
April 15, 2009
Stroke trials: a shift to shift analysis?
Devin L Brown, Christopher S Coffey
Communications in Statistics: Theory and Methods
|
January 28, 2014
Properties of Doubly-Truncated Gamma Variables
Christopher S Coffey, Keith E Muller
Drugs in R&D
|
July 1, 2008
Adaptive clinical trials: progress and challenges
Christopher S Coffey, John A Kairalla
Communications in Statistics: Theory and Methods
|
December 6, 2013
Some Distributions and Their Implications for an Internal Pilot Study With a Univariate Linear Model
Christopher S Coffey, Keith E Muller
Clinical Trials (London, England)
|
February 5, 2013
Monitoring futility in a two-by-two factorial design: the SPS3 experience
Leslie A McClure, Christopher S Coffey, George Howard
Stroke
|
June 11, 2005
Is Bayesian analysis ready for use in phase III randomized clinical trials? Beware the sound of the sirens
George Howard, Christopher S Coffey, Gary R Cutter
Page
of 17